Akums gets DCGI nod for triple combination diabetes medication
Glenmark Pharmaceuticals Limited, an innovation driven, global pharmaceutical company has launched the first triple fixed-dose combination Teneligliptin with Pioglitazone and Metformin in India.
LYON, France--(BUSINESS WIRE)--POXEL SA (Euronext : POXEL - FR0012432516), clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced positive histology results for DESTINY-1 (Deuterium-stabilized R-pioglitazone [PXL065] Efficacy and Safety Trial In NASH), the dose-ranging Phase 2 trial of PXL065 for the treatment of NASH. PXL065 is a novel, proprietary deuterium-stabilized R-stereoisomer of pioglitazone which has reduced PPAR? activity, but retains non-genomic thiazolidinedione (TZD) actions.
LYON, France--(BUSINESS WIRE)--POXEL SA (Euronext : POXEL - FR0012432516), clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced positive top-line results for DESTINY-1 (Deuterium-stabilized R-pioglitazone [PXL065] Efficacy and Safety Trial In NASH), the dose-ranging Phase 2 trial of PXL065 for the treatment of NASH. PXL065 is a novel, proprietary deuterium-stabilized R-stereoisomer of pioglitazone which has reduced PPAR? activity but retains non-genomic thiazolidinedione (TZD) actions.
Mumbai, April 26, 2022: Glenmark Pharmaceuticals Limited (Glenmark), an innovati ..
LYON, France--(BUSINESS WIRE)--POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to PXL065 for the treatment of patients with adrenomyeloneuropathy (AMN), the most common form of X-linked adrenoleukodystrophy (ALD). PXL065 is a novel, proprietary deuterium-stabilized R-stereoisomer of pioglitazone that is preparing to enter into a Phase 2a clinical Proof-of-Concept (POC) biomarker study midyear.
Enforcement Report - Week of February 2, 2022
Enforcement Report - Week of February 12, 2020
Six years’ efforts of a diabetologist working in a hospital in Chennai have finally forced the Union health ministry to direct his complaints on enquiry over reasons for banning pioglitazone to the Indian Council of Medical Research (ICMR) for investigation and necessary action. Pioglitazone, a drug to treat type 2 diabetes mellitus (T2DM), was banned in India on June 18, 2013.
French biopharmaceutical firm Poxel has commenced a Phase Ib clinical trial for the treatment of non-alcoholic steatohepatitis (NASH) with its investigational medicine, PXL065.